| Private Placement / Financing Transactions
MapLight: The company raised $225 million of Series C venture funding in a deal led by Novo Holdings on October 30, 2023, putting the company’s pre-money valuation at $240 million. Cowen Healthcare Investments, 5AM Ventures, and other undisclosed investors also participated in the round. The company is an operator of a biopharmaceutical business intended to discover novel treatments for brain disorders.
Terremoto Biosciences: The company raised $175 million of Series B venture funding from OrbiMed, EcoR1 Capital, and Third Rock Ventures on November 2, 2023. Novo Holdings, Cormorant Capital, and other undisclosed investors also participated in the round. The company is a developer of a drug delivery and discovery platform for small-molecule medicines.
Gate Bioscience: The company raised $60 million of Series A venture funding in a deal led by Versant Ventures and Andreessen Horowitz on November 1, 2023. GV and ARCH Venture Partners also participated in the round. The company is a developer of small molecule drugs intended to selectively eliminate harmful extracellular proteins inside cells, and prevent them from emerging to cause disease.
Covera Health: The company raised an estimated $50 million of Series C venture funding in a deal led by Insight Partners on November 1, 2023, putting the company’s pre-money valuation at $200 million. Green Meadow Ventures, Equity Group Investments and other undisclosed investors also participated in the round. The company is a provider of analytics-based programs intended to reduce medical misdiagnoses and improve quality of care.
Imagine Pharma: The company raised $40 million of Series A venture funding from IP Investors LLC on October 31, 2023. The company is a developer of a drug discovery and development platform intended to provide oral delivery of therapeutic and regenerative medicine.
Stellaromics: The company raised $25 million of Series A venture funding from Plaisance Capital Management and other undisclosed investors on November 2, 2023. The company is a developer of STARmap technology designed to optically extract multi-omic information from biological tissue.
Genome Insight: The company raised $23 million of Series B2 venture funding from Timefolio Capital, Samsung Venture Investment and SCL Group on November 1, 2023. Ignite Innovation, Asan Foundation and other undisclosed investors also participated in the round. The company is a developer of a genome-based big data platform for personalized precision medicine.
Aqtual: The company raised $16 million of Series A venture funding in a deal led by Genoa Ventures, Manta Ray Ventures and Yu Galaxy on October 31, 2023, putting the company’s pre-money valuation at $21 million. The company is a developer of a novel analytical platform for cancer drug treatment.
ProJenX: The company raised $15 million of Series A venture funding in a deal led by Medical Excellence Capital on November 2, 2023. The company is an operator of a clinical-stage biopharmaceutical company intended to treat Amyotrophic Lateral Sclerosis and other neurodegenerative diseases.
Jana Care: The company raised $13.2 million of venture funding from undisclosed investors on November 2, 2023. The company is a developer of a mobile diagnostic platform for diabetes diagnosis and treatment.
Jona: The company raised $5 million of venture funding in a deal led by Breyer Capital, Kicker Ventures and Meridian Street Capital on November 1, 2023. The company is an operator of an AI-based platform intended to interpret microbiome tests.
Reprise Biomedical: The company raised $4.5 million of venture funding from undisclosed investors on November 1, 2023. The company is a developer of biological medical products designed to support cellular integration.
Gregor Diagnostics: The company raised $4.4 million of venture funding in the form of convertible debt from undisclosed investors on October 31, 2023. The company is an operator of a molecular diagnostics business intended to develop a screening test for prostate cancer.
AltaThera Pharmaceuticals: The company received development capital from Thornapple River Capital in November 2023. The company is a developer of specialty pharmaceuticals intended to serve pediatric cardiac patients and adult Atrial Fibrillation patients.
Exogene: The company raised an undisclosed amount of venture funding from Beresford Ventures in November 2023. The company is an operator of a biotechnology platform intended to discover novel T-cell receptor-based therapies to treat advanced solid tumours.
Hillstar Bio: The company raised an undisclosed amount of venture funding from LifeArc Ventures in November 2023. The company is a developer of autoimmune drugs for the biotechnology research market to address unmet medical needs.
Hinge Bio: The company received an undisclosed amount of development capital from Thornapple River Capital in November 2023. The company is an operator of a biotech business developing a new class of binding therapeutics and diagnostics.
NaNotics: The company raised an undisclosed amount of venture funding from Methuselah Foundation and LifeSpan Vision Ventures on October 30, 2023. The company is a developer of a nano-medical platform designed to treat solid tumor cancers and autoimmune diseases.
Paradox Immunotherapeutics: The company raised an undisclosed amount of venture funding from Beresford Ventures in November 2023. The company is an operator of a biotech business intended to develop front-line monoclonal antibody (mAb) treatment for protein misfolding diseases.
Uplift Labs: The company is in the process of raising venture funding on November 1, 2023. The company is a developer of a motion analysis platform that uses artificial intelligence to offer real-time movement analysis.
|
